ASP Isotopes Inc. (NasdaqCM:ASPI) entered into a share purchase agreement to acquire 51% stake in Pet Labs Pharmaceuticals Proprietary Limited from Nucleonics Imaging Proprietary Limited for $2 million on October 30, 2023. Under the Purchase Agreement, ASP Isotopes has agreed to purchase from the Nucleonics, 51 ordinary shares in the issued share capital of PET Labs representing 51% of the issued share capital of PET Labs. The Company agreed to pay to the Seller an aggregate of $2 million for the Initial Sale Shares, of which aggregate amount $0.5 million is payable on the completion of the sale of the Initial Sale Shares and $1.5 million is payable on demand after one calendar year from the agreement date. ASP Isotopes Inc. has an option to purchase from the Seller the remaining 49 ordinary shares in the issued share capital of PET Labs, representing the remaining 49% of the issued share capital of PET Labs. DLA Piper South Africa Services (Pty) Ltd acted as legal advisor to ASP Isotopes Inc.

ASP Isotopes Inc. (NasdaqCM:ASPI) completed the acquisition of 51% stake in Pet Labs Pharmaceuticals Proprietary Limited from Nucleonics Imaging Proprietary Limited on October 30, 2023. Per the Share purchase agreement, the Company has agreed to pay a total of $2,000,000 for the shares in two installments. The first installment of $500,000 was paid in November 2023. In January 2024, the Company paid $264,750 towards the balance due. The remaining balance of $1,235,250 is due upon demand any time after October 31, 2024 and is expected to be paid in November 2024.